Diagnostic Performance of Plasma Levels of sST2 (Soluble Suppression of Tumorigenicity 2) in the Evaluation of Hypervolemia in Hemodialysis Patients: A Comparative Analysis With Traditional and Alternative Biomarkers
Emre Can Hartavi,
Sami Uzun,
Serhat Karadağ,
Emre Hoca,
Abdülkadir Çelik,
Hüseyin Oğuz,
Gamze Ekin Yılmaz,
Özlem Menken,
Egemen Cebeci Hemodialysis International
· Wiley
· 2026-10-06
· DOI: 10.1111/hdi.70092
Аннотация у издателя не опубликована — полный текст доступен по ссылке ниже.
Emre Can Hartavi, Sami Uzun, Serhat Karadağ, Emre Hoca, Abdülkadir Çelik, Hüseyin Oğuz et al. Diagnostic Performance of Plasma Levels of sST2 (Soluble Suppression of Tumorigenicity 2) in the Evaluation of Hypervolemia in Hemodialysis Patients: A Comparative Analysis With Traditional and Alternative Biomarkers. // Hemodialysis International. – 2026. – DOI: 10.1111/hdi.70092. – URL: https://onlinelibrary.wiley.com/doi/10.1111/hdi.70092?af=R
Emre Can Hartavi, Sami Uzun, Serhat Karadağ, Emre Hoca, Abdülkadir Çelik, Hüseyin Oğuz, Gamze Ekin Yılmaz, Özlem Menken, & Egemen Cebeci (2026). Diagnostic Performance of Plasma Levels of sST2 (Soluble Suppression of Tumorigenicity 2) in the Evaluation of Hypervolemia in Hemodialysis Patients: A Comparative Analysis With Traditional and Alternative Biomarkers. Hemodialysis International. https://doi.org/10.1111/hdi.70092
Emre Can Hartavi, et al. “Diagnostic Performance of Plasma Levels of sST2 (Soluble Suppression of Tumorigenicity 2) in the Evaluation of Hypervolemia in Hemodialysis Patients: A Comparative Analysis With Traditional and Alternative Biomarkers.” Hemodialysis International, 2026. doi:10.1111/hdi.70092.
@article{Hartavi2026,
title = {Diagnostic Performance of Plasma Levels of sST2 (Soluble Suppression of Tumorigenicity 2) in the Evaluation of Hypervolemia in Hemodialysis Patients: A Comparative Analysis With Traditional and Alternative Biomarkers},
author = {Hartavi, Emre Can and Uzun, Sami and Karadağ, Serhat and Hoca, Emre and Çelik, Abdülkadir and Oğuz, Hüseyin and Yılmaz, Gamze Ekin and Menken, Özlem and Cebeci, Egemen},
journal = {Hemodialysis International},
year = {2026},
doi = {10.1111/hdi.70092},
url = {https://onlinelibrary.wiley.com/doi/10.1111/hdi.70092?af=R}
}
ABSTRACT Approximately 5% of patients who develop renal rupture lack an identifiable underlying lesion, such as tumours, hydronephrosis, or vascular malformations. In this case report, we detail a case with a left renal rupture of a...
ABSTRACT Aim Both high and low body mass index (BMI) have been reported to be associated with a higher risk of chronic kidney disease (CKD) progression. However, whether this association varies across CKD stages remains unclear. We...
Nature Reviews Nephrology, Published online: 17 November 2026; doi:10.1038/s41581-026-01151-4 The concept of cardiovascular–kidney–metabolic (CKM) syndrome supports an integrated, multidisciplinary approach to improve patient outcomes....
ABSTRACT Introduction Patients on hemodialysis have an increased risk of sudden cardiac death and an increased cardiac arrhythmia burden due to large fluid and electrolyte shifts, especially during the long inter‐dialytic period....